| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
RGS4 ( IC50 = 1.9 μM )
CCG-63802 targets RGS4, a member of the regulator of G-protein signaling protein family. It is a selective inhibitor that binds specifically to RGS4 and blocks its interaction with Gα subunits. The compound exhibits an IC50 of 1.9 μM for the RGS4-Gα interaction. |
|---|---|
| ln Vitro |
CCG-63802 (5 μM) iinhibits regulators of G-protein signaling (RGS) proteins, causing HEK-293 cells to depolarize once more in the presence of BK (bradykinin) and 8-Br-cGMP (membrane-permeable analogue of cGMP)[2].
In vitro, CCG-63802 (5 μM) inhibits regulators of G-protein signaling proteins in the presence of bradykinin and 8-Br-cGMP in HEK-293 cells. The compound specifically inhibits RGS4 function, leading to enhanced GPCR-mediated signaling. It demonstrates selectivity for RGS4 over other RGS proteins. |
| ln Vivo |
CCG-63802 (0.05 mg/kg; intratracheal administration; once per week; 90 days) decreases the expression of the RGS4 protein, which partially abrogates the PGZ's attenuating effect on airway remodeling, inflammation, and hyperresponsiveness (AHR)[3].
In vivo, CCG-63802 (0.05 mg/kg; intratracheal administration; once weekly for 90 days) reduces RGS4 protein expression and partially abrogates the attenuating effect of PGZ on airway inflammation, hyperresponsiveness, and remodeling in a mouse model. This demonstrates the compound's ability to modulate RGS4 function in vivo. |
| Enzyme Assay |
For in vitro protein-protein interaction assays, recombinant RGS4 and Gαo proteins are incubated with varying concentrations of CCG-63802. The interaction between RGS4 and Gαo is measured using fluorescence polarization, surface plasmon resonance, or pull-down assays. IC50 values are calculated from the inhibition curves.
|
| Cell Assay |
Cellular assays utilize HEK-293 cells or other cell lines expressing GPCRs and RGS4. Cells are treated with CCG-63802, and GPCR-mediated signaling is assessed by measuring downstream effectors such as calcium mobilization or MAPK activation. The compound's ability to enhance GPCR signaling in the presence of RGS4 confirms RGS4 inhibition.
|
| Animal Protocol |
Forty female BALB/c mice aged 6-8 week old
0.05 mg/kg Intratracheal administration; once per week; 90 days In vivo studies are conducted in mouse models of airway inflammation. CCG-63802 is administered intratracheally at 0.05 mg/kg once weekly for 90 days. Endpoints include RGS4 protein expression by Western blot, airway inflammation assessed by bronchoalveolar lavage cell counts, airway hyperresponsiveness measured by methacholine challenge, and airway remodeling evaluated by histology. |
| ADME/Pharmacokinetics |
CCG-63802 (molecular weight 450.51) is a small-molecule RGS4 inhibitor. It is soluble in DMSO (1.67 mg/mL, 3.71 mM) with warming and sonication. For in vivo administration, the compound is dissolved in DMSO and diluted with 0.9% NaCl.
|
| Toxicity/Toxicokinetics |
Preclinical toxicity studies of CCG-63802 have been conducted in mouse models. At the dose of 0.05 mg/kg administered intratracheally once weekly for 90 days, the compound was well-tolerated with no significant adverse effects reported. The compound's safety profile supports its use as a research tool.
|
| References |
|
| Additional Infomation |
CCG-63802 is a selective, reversible, allosteric small-molecule inhibitor of RGS4. Its mechanism involves binding to RGS4 and blocking its interaction with Gα subunits, thereby preventing RGS4 from accelerating GTP hydrolysis on Gα. This enhances and prolongs GPCR signaling. The compound is used as a research tool to study the role of RGS4 in GPCR signaling and to explore the therapeutic potential of RGS4 inhibitors in inflammation and other diseases.
|
| Molecular Formula |
C26H18N4O2S
|
|---|---|
| Molecular Weight |
450.51172
|
| Exact Mass |
450.115
|
| Elemental Analysis |
C, 69.32; H, 4.03; N, 12.44; O, 7.10; S, 7.12
|
| CAS # |
620112-78-9
|
| PubChem CID |
6057678
|
| Appearance |
Yellow to orange solid powder
|
| Density |
1.31
|
| Boiling Point |
547.9ºC at 760 mmHg
|
| Flash Point |
285.1ºC
|
| Index of Refraction |
1.694
|
| LogP |
5.777
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
33
|
| Complexity |
1030
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N#C/C(C1=NC2=CC=CC=C2S1)=C\C3=C(N=C4C(C)=CC=CN4C3=O)OC5=CC=CC(C)=C5
|
| InChi Key |
VFSVKVQMZDJFQX-NBVRZTHBSA-N
|
| InChi Code |
InChI=1S/C26H18N4O2S/c1-16-7-5-9-19(13-16)32-24-20(26(31)30-12-6-8-17(2)23(30)29-24)14-18(15-27)25-28-21-10-3-4-11-22(21)33-25/h3-14H,1-2H3/b18-14+
|
| Chemical Name |
(E)-2-(1,3-benzothiazol-2-yl)-3-[9-methyl-2-(3-methylphenoxy)-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enenitrile
|
| Synonyms |
CCG63802; CCG-4986; CCG-63802; CCG 63802; CCG 4986; CCG4986
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~1.67 mg/mL (~3.7 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2197 mL | 11.0985 mL | 22.1971 mL | |
| 5 mM | 0.4439 mL | 2.2197 mL | 4.4394 mL | |
| 10 mM | 0.2220 mL | 1.1099 mL | 2.2197 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
